No not yet, but page 3 sums it all up:
The Directors believe this trip has great significance for the Company. It will coincide with the
expected regulatory approval of Ropren – the first Russian developed pharmaceutical to be
registered in Russia for some 20 years. It will also showcase Ropren at a time when there is
an explosion in the incidence of liver disease – not just in Russia but throughout the world.
Cheers Greg
- Forums
- ASX - By Stock
- SLA
- drug not approved...
drug not approved..., page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)